Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2026

On August 28, 2026 Elicera Therapeutics AB (publ) reported interim results for 1 January – 30 June 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Second quarter (January-March 2026)

Operating profit/loss amounted to SEK -6,305,471 (-2,892,341)
Loss for the period amounted to SEK -6,261,763 (-2,732,070)
Cash flow from operating activities totaled SEK -3,950,514 (-5,991,211)
Earnings per share before and after dilution totaled SEK -0.12 (-0.06)

Period (January-June 2026)

Operating profit/loss amounted to SEK -11,422,250 (-10,961,745)
Loss for the period amounted to SEK -11,321,823 (-10,745,532)
Cash flow from operating activities totaled SEK -10,932,926 (-6,736,135)
Earnings per share before and after dilution totaled SEK -0.22 (-0.25)

Key events during the quarter

An extra shareholders meeting May 8 approved the boards proposal for a new rights issue at SEK 72.8 m
Elicera’s CSO takes temporary leave to undergo medical treatment – Di Yu appointed Acting Chief Scientific Officer (CSO)
Elicera Therapeutics announces that the final reporting and final payment (SEK 1.4 m) from the EIC Accelerator for the CARMA study have been approved
Elicera’s new issue subscribed at 75 % and Elicera receive SEK 54.6 m before issuing costs
Elicera receives positive feedback from Swedish MPA on Planned Clinical Study with ELC-401 in glioblastoma
Elicera’s annual general meeting June 25 elects Margareth Jorvid as new chair

Key events during the period

Elicera announces final data from its Phase I/IIa trial demonstrating a favourable safety profile and promising efficacy signals of oncolytic virus ELC-100 in neuroendocrine tumors
Elicera provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway
Elicera reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients
Elicera’s CSO Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden)
Elicera receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate
Elicera Announces Swedish Cancer Society’s Senior Investigator Award to Chief Development Officer Di Yu

Key events after the end of the period

Last patient treated in the Phase I part of the CARMA study – tumor responses in 10 of 11 patients evaluated to date
Elicera gathers management in Uppsala – CEO transition begins and recruitment of a new CEO has started
Elicera Therapeutics appoints Johan Liwing as new CEO
No other key events that impact earnings or the financial position occurred after the end of the period.

CEO Comments

Updated results from the CARMA study show tumor response in 91 percent of patients

We are pleased to report continued strong results from our clinical Phase I/IIa study CARMA with ELC-301. The twelfth and final patient in the study’s Phase I portion has

now been treated, and among the eleven patients evaluated so far, all have achieved disease control one month after treatment. As many as 91 percent (10 of 11) have had an objective tumor response, including six patients with a complete metabolic response, meaning no remaining active disease. Of these six, four have maintained a

complete response at the most recent follow-up, with the longest-responding patient now disease-free for at least 18 months and another patient for at least 12 months.

These are early but important signs that the responses may be durable rather than temporary, which strengthens our confidence that both ELC-301 and our iTANK platform, together with other CAR T-cell programs, could be decisive even for patients who have stopped responding to their previous CAR T treatment. Particularly interesting is that three of the eleven evaluated patients had previously been treated with other CAR T therapy but subsequently relapsed, and that all achieved disease control after treatment with ELC-301; two of them obtained an objective tumor response, of which one was a complete metabolic response.

As soon as the last patient has undergone their follow-up evaluation, the study’s independent Data Safety Monitoring Board (DSMB) will assess the third and final cohort, which will determine the recommended dose for the study’s continued

dose-expansion part (Phase IIa) with an additional six patients.

Magnus Essand and Di Yu receive prestigious awards – the organization stands strong

We are very proud that our co-founder and Chief Scientific Officer, Professor Magnus Essand, was awarded the Swedish Cancer Society’s Cancer Researcher of the Year award during spring 2026 for his pioneering research in immunotherapy targeting cancer — a fine and well-deserved recognition also of the scientific foundation on which Elicera’s development programs rest. At roughly the same time, our Chief Development Officer Di Yu was awarded the Swedish Cancer Society’s prestigious Senior Investigator Award,which provides funding for his research over the next three

years. Together, these awards underscore the scientific quality that permeates the company.

We have previously announced in a press release that Magnus took temporary leave in May from his commitments to the company and the board in order to undergo

medical treatment. We wish him all strength during this time. Di Yu, who has already held the greatest operational responsibility for our scientific and clinical development

in recent years, has, as previously announced, stepped in as Deputy CSO effective immediately to ensure continuity.

In recent years, the company has progressively broadened the team, including by recruiting several senior researchers and an experienced clinical project manager,

in order to reduce dependence on individual key personnel.

Our ongoing operations, including the CARMA study and preparations for our first clinical study in the ELC-401 program, are continuing entirely according to plan.

Strengthened financial position following a successful rights issue

During the second quarter, we carried out a partially guaranteed rights issue of approximately SEK 72.8 million, which after the subscription period ended on May 29 provided the company with approximately SEK 54.6 million before transaction costs. The issue strengthens our financial position and secures capital to complete the recruitment and treatment of all 18 planned patients in the CARMA study.

The capital also enables us to accelerate preparations for the planned first clinical study with ELC-401, including secured funding for process development and tech transfer of the manufacturing process to our chosen manufacturing partner. I want to extend my sincere thanks to our existing shareholders for your continued trust and support in the rights issue, and at the same time warmly welcome our new shareholders.

Important regulatory milestone for ELC-401

In addition to funding the preparatory work, during the quarter we reached an important milestone for ELC-401, our iTANK-armed CAR T-cell candidate targeting IL13Rα2 in the treatment of glioblastoma. We held a scientific advice meeting with the Swedish Medical Products Agency (Läkemedelsverket) regarding the planned first clinical study.

The agency provided supportive and constructive guidance on the clinical protocol, the dose-escalation strategy, and the manufacturing specifications, and confirmed that our preclinical data package is now considered sufficient to initiate our clinical development phase. This guidance gives us a clear framework as we now finalize the study design in parallel with process development and tech transfer, and is an important milestone on the path to starting the first clinical study with ELC-401, which targets solid tumors in the brain. Glioblastoma is a difficult-to-treat disease with a great need for new treatment options. We also had a patent approved in Japan for ELC-401 during the year, further strengthening our intellectual property protection for the program in an important market.

Next step in the development of ELC-100 still under evaluation

In the recently completed clinical Phase I/IIa study of ELC-100 (oncolytic virus) in 12 patients with advanced, metastatic neuroendocrine tumors, a favorable safety

profile was observed with no dose-limiting toxicity. Among the eight evaluable patients, partial response was noted in two, providing early evidence of antitumor activity in a disease with a significant unmet medical need. We are gathering input from Key Opinion Leaders in neuroendocrine tumors. No decision has yet been made regarding the next step in the program’s development.

Margareth Jorvid new Chair of the Board

At the Annual General Meeting, Margareth Jorvid was elected as the new Chair of the Board of Elicera. Margareth has over 30 years of experience in the pharmaceutical industry, with previous roles at international companies such as Hoechst Marion Roussel, including assignments in both Stockholm and Paris. Since 2006 she has run her own life science company focused on regulatory affairs and quality assurance. She holds an MSc in Pharmacy and an MBA, and has previously served as Chair of the international industry organization TOPRA (2005–2006), where she is also a Fellow and honorary member — a role that has given her

broad experience of board and organizational work at an international level.

Agneta Edberg, who has served as Chair since 2021, stepped down from the chairperson role and was re-elected as an ordinary board member. Her experience and commitment therefore remain part of the board’s work. We want to extend a warm thank you to Agneta for her significant contributions as Chair over the years, and at the same time warmly welcome Margareth to the role.

Johan Liwing is appointed as new CEO

Finally, I want to inform you that the company is entering a new organizational phase, which is a result of Elicera’s successful development and a natural step in the company’s maturation. The board’s and my assessment is that having a unified management team based in the Uppsala region, close to the core operations and the company’s development team, provides the best conditions for building the team that the next phase of program development requires. Since I am based in Gothenburg and, for family reasons, am unable to move to Uppsala, Johan Liwing has been appointed by the Board of Directors as the new CEO effective 1 September 2026. I will remain employed by the company until 31 October 2026 and will also thereafter be available to ensure an orderly handover to my successor. I have great confidence that both the board and the organization are well equipped to lead Elicera forward into the next phase.

(Press release, Elicera Therapeutics, AUG 28, 2026, View Source;30-june-2026 [SID1234670389])

Elicera Therapeutics receives Notice of Allowance for U.S. patent application protecting the ELC-401 CAR T-cell candidate

On August 28, 2026 Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company’s commercially available platform iTANK, reported that it has received a Notice of Allowance from the USPTO (United States Patent and Trademark Office) regarding its patent application for the CAR T-cell candidate ELC-401.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent application protects Elicera’s special antibodies that recognize and bind to the protein IL-13Ra2 (which is often present in large quantities on cancer cells, particularly brain tumors), as well as uses thereof in cancer treatment, such as CAR-T cell therapies.

The patent gives Elicera exclusive rights in U.S. to develop and sell treatments based on these anti-IL-13Ra2 antibodies and related technologies for cancer treatment. This strengthens the company’s protection for ELC-401 (its CAR-T cell candidate against glioblastoma) and other future products based on the same principle.

"Securing patent protection for our anti-IL-13Ra2 antibodies, used in CAR T-cell treatments, is commercially very significant because the United States is the world’s largest and most valuable market for advanced cell and gene therapies. Exclusive protection there strengthens our ability to develop, partner and commercialize ELC-401 and future products based on the same technology", says Elicera’s CEO, Jamal El-Mosleh.

About Glioblastoma and ELC-401
Glioblastoma is the most aggressive primary brain tumor, with a median survival of approximately 15 months despite standard treatments (surgery, radiotherapy, and chemotherapy). ELC-401 is designed to target IL13Ra2-positive tumors while using the iTANK platform to stimulate endogenous immune responses against additional tumor antigens, potentially overcoming heterogeneity and immunosuppression in GBM.

About the iTANK platform
The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company’s own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled "CAR T cells expressing a bacterial virulence factor triggers potent bystander antitumor responses in solid cancers" (DOI number: 10.1038/s41551-022-00875-5) can be found here: View Source More information about iTANK platform is available here: View Source

(Press release, Elicera Therapeutics, AUG 28, 2026, View Source [SID1234670388])

HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

On August 28, 2026 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) reported that the New Drug Application (NDA) for fanregratinib (HMPL-453), a novel, selective, oral inhibitor targeting FGFR 1/2/3, has been granted conditional approval by the China National Medical Products Administration ("NMPA") for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma ("ICC") with fibroblast growth factor receptor ("FGFR") 2 fusion or rearrangement who have previously received systemic therapy. Fanregratinib will be marketed in China under the brand name ATLED.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ICC is a highly aggressive malignancy arising from the intrahepatic biliary epithelium. It accounts for 8.2-15.0% of primary liver cancers, and consequently it is the second most common type after hepatocellular carcinoma. In recent years, the incidence of ICC has continued to rise, with a 5-year overall survival rate of approximately 9%.[1] Approximately 10-15% of ICC patients globally have tumors harboring FGFR2 fusions or rearrangements.[2],[3]

The approval is supported by data from the Phase II registration cohort of the single-arm, multi-center, open‑label, pivotal Phase II/IIIb clinical trial of ATLED in China (NCT04353375). The results were recently presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Gastrointestinal Cancers Congress 2026. The study met its primary endpoint, demonstrating an Independent Review Committee (IRC)-assessed objective response rate (ORR) of 42.5% (95% CI: 30.0%–53.6%) in pretreated advanced ICC patients harboring FGFR2‑fusions/rearrangements, representing a strong, clinically meaningful response.

Key secondary endpoints showed consistent clinical activity and a rapid onset of action, with a median time to response of 1.4 months. Median duration of response (DoR) was 6.9 months (95% CI: 5.6–8.5) and disease control rate (DCR) reached 83.9% (95% CI: 74.5%–90.9%). Furthermore, the median progression-free survival (PFS) was 6.9 months (95% CI: 4.1–8.2), while the median overall survival (OS) was 16.6 months (95% CI: 12.4–16.6).

"As a major and with historically limited targeted options. We are thrilled by the NMPA approval of ATLED, which directly addresses this critical therapeutic gap in China," said Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED. "This approval unlocks an important new treatment alternative for a substantial population of pretreated advanced ICC patients. We are fully prepared to leverage our established commercial infrastructure to bring this precision medicine to patients as rapidly as possible."

The Phase IIIb portion of the trial will serve as the confirmatory study to further validate the clinical benefits and safety of ATLED in this setting. Enrollment for this confirmatory cohort was initiated in January 2026.

About ATLED
ATLED (fanregratinib, HMPL‑453) is a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3. Aberrant FGFR signaling has been found to be a driving force in tumor growth, promotion of angiogenesis and resistance to anti-tumor therapies. Abnormal FGFR gene alterations are believed to be the drivers of tumor cell proliferation in several solid tumor settings. HUTCHMED currently retain all rights to fanregratinib worldwide.

(Press release, Hutchison China MediTech, AUG 28, 2026, View Source [SID1234670387])

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

On August 27, 2026 JW Therapeutics reported interim results for the six months ended June 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, JW Therapeutics, AUG 27, 2026, View Source [SID1234671257])

Oncopeptides publishes Q2 report 2026

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!